Insulet | PODD - Des Atouts





Des Atouts Changement Date
Abbott USD 110.43B 23.72B 2026-03
Align Technology USD 6.31B 80.48M 2026-03
AtriCure USD 643.99M 10.19M 2026-03
Avanos Medical USD 1.05B 23.6M 2026-03
Baxter International USD 19.85B 209M 2026-03
Becton, Dickinson and Co. USD 50.83B 4.01B 2026-03
Boston Scientific USD 44.35B 678M 2026-03
Cardinal Health USD 56.69B 1.39B 2026-03
Cooper Companies USD 12.48B 58.1M 2026-03
Dexcom USD 6.63B 293.4M 2026-03
Edwards Lifesciences USD 13.32B 376M 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Globus Medical USD 5.44B 136.79M 2026-03
ICU Medical USD 4.01B 36.74M 2026-03
Inogen USD 307.01M 5.03M 2025-09
Insulet USD 2.99B 203.2M 2026-03
Integra LifeSciences USD 3.58B 24.28M 2026-03
J&J USD 200.89B 1.68B 2026-03
Medtronic USD 91.48B 139M 2025-12
Merit Medical Systems USD 2.72B 33.36M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Solventum Corp USD 14.1B 197M 2026-03
Stryker USD 46.29B 1.55B 2026-03
Tandem Diabetes Care USD 1.15B 272.28M 2026-03
Teleflex USD 6.78B 164.24M 2026-03
West Pharmaceutical Services USD 4.11B 160.2M 2026-03
Zimmer Biomet Holdings USD 22.72B 370.1M 2026-03